Mark Froimson is Director at Pacira Pharmaceuticals, Inc. (PCRX). They have made 5 open-market trades across 1 company since 2017, most recently 2026-06-10.
CIK 0001709050
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $20K since 2017, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 26,541 | $967K |
Shares reported on the most recent Form 4, priced at the 2026-06-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL | 2026-03-17 | 2026-03-19 | $21.81 | $11K | -0.7% | +9.5% | -0.6% |
| PCRX | BUY | 2024-08-12 | 2024-08-12 | $11.58 | $16K | +21.0% | +12.6% | +51.5% |
| PCRX | SELL | 2022-05-09 | 2022-05-11 | $59.37 | $59K | +7.2% | -5.2% | -0.9% |
| PCRX | SELL | 2021-03-15 | 2021-03-17 | $72.26 | $106K | +2.4% | -9.6% | -14.5% |
| PCRX | BUY | 2017-08-08 | 2017-08-16 | $37.13 | $4K | -2.4% | -0.4% | +7.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.